# US 2012/0251539 A1 · Methods and Compositions for the Treatment of Immune Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251539 A1
- Document ID: US20120251539A1
- Status: Published application
- Kind: A1
- Application number: 13/511,933
- Filed: 2010-11-23
- Published: 2012-10-04
- Earliest claimed: 2009-11-25
- Assignees: The University of North Carolina at Chapel Hill
- Inventors: Jenny P.-Y. Ting; Haitao Wen
- Web page: https://patentgrep.com/patent/US20120251539A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/47: from mammals
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins.

## Claims

### Claim 1

A method of treating an immune-related and/or inflammatory disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, whereby the plexin-A4 activity in said subject is reduced, thereby treating the immune-related disorder and/or inflammatory disorder.

### Claim 2

A method of reducing cytokine production in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, thereby reducing the cytokine production the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor of plexin-A4 activity is selected from the group consisting of a plexin-A4 fusion protein, a plexin-A4 antibody or an active fragment thereof, or any combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the plexin-A4 antibody or active fragment thereof is a monoclonal antibody or is derived from a monoclonal, antibody.

### Claim 5 (depends on 3)

The method of claim 3, wherein the plexin-A4 fusion protein comprises the extracellular domain of plexin-A4 and the Fc region of IgG.

### Claim 6 (depends on 5)

The method of claim 5, wherein the extracellular domain of plexin-A4 and the IgG1 Fc region is human.

### Claim 7 (depends on 5)

The method of claim 5, wherein the extracellular domain of plexin-A4 comprises the amino acid sequence of SEQ ID NO:7 and the IgG Fc region comprises the amino acid sequence of SEQ ID NO:8.

### Claim 8 (depends on 3)

The method of claim 3, wherein the plexin-A4 fusion protein comprises the amino acid sequence of SEQ ID NO:6.

### Claim 9 (depends on 1)

The method of claim 1, wherein the immune-related and/or inflammatory disorder is selected from the group consisting of sepsis, arthritis, hepatitis, systemic lupus erythematosus (SLE), multiple sclerosis, Guillain-Barre syndrome, Alzheimer's disease, colitis, psoriasis, contact hypersensitivity, retinitis, uveitis, malignancies, systemic lupus erythematosis, asthma, myocarditis, hepatitis, kidney diseases, diabetes, obesity, cardiovascular diseases, and inflammatory bowel disease, or any combination thereof.

### Claim 10 (depends on 3)

The method of claim 3, wherein the inhibitor is administered subcutaneously, intramuscularly, intraperitoneally, topically, intravenously, and any combination thereof.

### Claim 11

(canceled)

### Claim 12

A method of treating an immune-related and/or inflammatory disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, whereby the Sema3A activity in said subject is reduced, thereby treating the immune-related disorder and/or inflammatory disorder.

### Claim 13

A method of reducing cytokine production in a subject, comprising administering to the subject an effective amount of an inhibitor of Sema3A activity, thereby reducing the cytokine production the subject.

### Claim 14 (depends on 12)

The method of claim 12, wherein the inhibitor of Sema3A activity is selected from the group consisting of a Sema3A fusion protein, a Sema3A antibody or an active fragment thereof, or any combination thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the plexin-A4 antibody or active fragment thereof is a monoclonal antibody or is derived from a monoclonal antibody.

### Claim 16 (depends on 14)

The method of claim 14, wherein the Sema3A fusion protein comprises the amino acid sequence encoding Sema3A and the Fc region of IgG.

### Claim 17 (depends on 16)

The method of claim 16, wherein the amino acid sequence encoding Sema3A and the IgG 1 Fc region is human.

### Claim 18 (depends on 16)

The method of claim 16, wherein the amino acid sequence encoding Sema3A comprises the amino acid sequence of SEQ ID NO:13 and the IgG Fc region comprises the amino acid sequence of SEQ ID NO:8.

### Claim 19 (depends on 14)

The method of claim 14, wherein the Sema3A fusion protein comprises the amino acid sequence of SEQ ID NO:16.

### Claim 20 (depends on 12)

The method of claim 12, wherein the immune-related and/or inflammatory disorder is selected from the group consisting of sepsis, arthritis, hepatitis, systemic lupus erythematosus (SLE), multiple sclerosis, Guillain-Barre syndrome, Alzheimer's disease, colitis, psoriasis, contact hypersensitivity, retinitis, uveitis, malignancies, systemic lupus erythematosis, asthma, myocarditis, hepatitis, kidney diseases, diabetes, obesity, cardiovascular diseases, and inflammatory bowel disease, or any combination thereof.

### Claim 21 (depends on 14)

The method of claim 14, wherein the inhibitor is administered subcutaneously, intramuscularly, intraperitoneally, topically, intravenously, and any combination thereof.

### Claim 22

(canceled)
